[ad_1] A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease Control and Prevention on Friday recommended Pfizer‘s maternal vaccine that protects infants from respiratory syncytial virus, putting the shot on track to be available in the U.S. this…
[ad_1] CFOTO | Future Publishing | Getty Images The Food and Drug Administration on Monday approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of hospitalization among babies in the U.S. Pfizer’s RSV shot is already approved and available in the U.S. for older adults. It’s now the second…
[ad_1] Expectant parents could soon have another new option this fall to protect their newborns from RSV, or respiratory syncytial virus, the most common cause of hospitalization in American infants, after the Food and Drug Administration announced Monday that it has widened its approval for Pfizer’s Abrysvo vaccine to include expectant mothers. Pregnant women would…
[ad_1] It may still feel like summer, but the fall is quickly approaching — along with the risk of seasonal viruses. On “CBS Mornings” Monday, Dr. Céline Gounder, a CBS News medical contributor and editor-at-large for public health at KFF Health News, shared what you need to know about protecting yourself from COVID-19, the respiratory illness…
[ad_1] Many babies should get a shot soon after birth to protect them from RSV, or respiratory syncytial virus, a panel of the Centers for Disease Control and Prevention’s outside advisers voted Thursday. The recommendation clears the way for a new option experts have hailed as a historic advance to curb the leading cause of…
[ad_1] Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine. GSK claims New York-based Pfizer’s RSV vaccine, Abrysvo, infringes on four of its patents related to the antigen used in its own shot. related investing news “Upon information and…
[ad_1] Budrul Chukrut | Lightrocket | Getty Images GlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company’s new RSV vaccine to start off slower than it did for its blockbuster shingles shot. But she is confident that the new vaccine will drive future sales. “I think the uptake on this we…
[ad_1] The Food and Drug Administration announced Monday it had approved a new kind of immunization to protect babies from RSV, or respiratory syncytial virus. The drug, nirsevimab, is one of two new options doctors hope could soon prevent the leading cause of hospitalization facing American infants. Outside advisers to the federal government have previously…
[ad_1] Respiratory syncytial virus vial. Manjurul | Istock | Getty Images The Centers for Disease Control and Prevention on Thursday recommended that adults ages 60 and above receive a single dose of RSV vaccines from Pfizer and GSK after consulting their doctors. Outgoing CDC Director Rochelle Walensky signed off on the recommendation, which an advisory…
[ad_1] The first vaccines to guard against the respiratory illness RSV will soon be available for some older adults, ages 60 and over, after the CDC formally backed recommendations for the shots. The move, announced Thursday, followed a vote at a meeting of the CDC’s Advisory Committee on Immunization Practices earlier this month on the new…
